Loading...
•
Mar 31, 2024
10X Genomics Q1 2024 Earnings Report
Reported a 5% increase in revenue driven by Spatial revenue, and shipped four major new products.
Key Takeaways
10x Genomics reported a 5% increase in revenue for Q1 2024, driven by Spatial revenue. The company shipped four major new products and is maintaining its full year 2024 revenue guidance of $670 million to $690 million.
Revenue was $141.0 million for the first quarter, a 5% increase over the corresponding period of 2023, driven by Spatial revenue.
Shipped Visium HD Spatial Gene Expression, enabling whole transcriptome spatial discovery at single cell-scale resolution.
Shipped two major new Chromium products powered by GEM-X, the next generation of the company's leading single cell technology architecture.
Shipped the Xenium multi-modal cell segmentation product and a new gene panel optimized for immuno-oncology applications.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
10x Genomics is maintaining its previously announced full year 2024 revenue guidance of $670 million to $690 million, representing 8% to 12% growth over full year 2023 revenue.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...